GSK partners with Malaysian Urological Association, MMA
In support of the Blue Cap Movement, GlaxoSmithKline (GSK) Pharmaceutical Sdn Bhd embarks on a partnership with the Malaysian Urological Association (MUA) and Malaysian Medical Association (MMA) to further promote awareness and education on benign prostatic hyperplasia (BPH).
The partnership will start with the loan of 12 uroflow meters from GSK to MUA, said Dato’ Dr Selvalingam Sothilingam, president of the MUA. The machines will be made available to GPs in the country. Interested clinics or GPs who currently have no access to uroflow meters can apply to borrow the devices via the MUA’s website. The duration of the loan is set at one day a year. It is hoped that this initiative will help GPs to identify men suffering from BPH and to allow early intervention.
At the same time, GSK will be launching six online continuing professional development (CPD) courses, said Ramesh Balakrishnan, business unit director, Classic and Established Products, GSK. The courses will be available on both GSK and MMA’s websites. Ramesh said the aim of the courses is to help increase confidence and competence in screening, diagnosing and treating BPH. The topics of the courses range from anatomy to various treatment options available locally.
When faced with a condition such as BPH where the individual may feel embarrassed or vulnerable, it is vital to redefine the approach men usually take in addressing prostate-related health, said Ramesh. Through this partnership with MUA and MMA, GSK is proud to be at the forefront of men’s health to lead the national conversation about BPH and to reduce the stigma associated with its symptoms, he continued.
Besides improving access to uroflow meters and developing CPD modules, the partnership will feature a number of public materials that aim to illustrate the magnitude of BPH symptoms in older men; educate on the risk of complications that may arise from undiagnosed and untreated BPH; and encourage those suffering from symptoms to seek medical help.
The risk of BPH is increased in men aged 40 and older; those who have a positive family history of BPH; those with existing medical conditions such as type 2 diabetes, obesity and cardiovascular disease; and men who lack the right amount of exercise, said Selvalingam. By improving accessibility and availability of screening and diagnostic tools, healthcare professionals will be able to proactively address BPH in patients at higher risk of BPH. Hopefully, this will also help clinicians to break across a patient’s reservations, he said.